NEW YORK (GenomeWeb News) – The Center for Autism and Related Disorders and molecular diagnostics firm Lineagen today announced a partnership to offer the FirstStep genetic test to patients.
Lineagen's whole-genome genetic test for autism spectrum disorders will be integrated with pre- and post-genetic counseling services and personalized reporting and will be available to patients in CARD's Skills program. The program is designed to meet clinical guidelines recommending chromosomal microarray analysis as a first-line genetic test to evaluate individuals with ASD.
"Recent scientific literature and clinical guidelines have recommended genetic testing and counseling for children with ASDs," CARD Founder and Executive Director Doreen Granpeesheh said in a statement. "In selecting a partner in this area, CARD chose Lineagen's FirstStepDx because it includes the most advanced technology complemented with the personal service similar to that provided by CARD to each patient and family."
Lineagen is based in Salt Lake City. Earlier this year it began incorporating Affymetrix's GeneChip technology into its genetic evaluation service for patients with developmental delay, intellectual disability, and autism spectrum disorders.